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Abstract: Problem statement: The prevalence of Alzheimer’s disease is increasing but the efficacy of 
treatment is still very limited due to various factors including the blood brain barrier. Recent findings 
demonstrated the crucial role of oxidative stress on the pathophysiology of disease. In addition the 
burden of blood brain barrier can be overcome by nasal administration and vesicle-carrier mediated 
delivery system.  Based on the potent antioxidant effect of quercetin and the burden of blood brain 
barrier, we hypothesized that the nasal administration of quercetin liposomes could protect against 
neurodegeneration in Alzheimer’s disease. Approach: This study was designed to evaluate the effect 
and possible action of nasal administration of quercetin liposomes on neurodegeneration in animal 
model of Alzheimer’s disease. Male Wistar rats were pretreated with quercetin liposomes, containing 
0.5 mg of quercetin in 20 μL via intranasal route once daily continually for 2 weeks before and 1 week 
after AF64A administration. After the quercetin liposomes treatment, the density of neurons and 
cholinergic neurons in hippocampus were assessed using histochemical and immunohistochemical 
techniques whereas the activities of Superoxide Dismutase (SOD), Catalase (CAT), Glutathione 
Peroxidase (GPx) and Malondialdehide (MDA), a lipid peroxidation product, were determined using 
biochemical assays. Results: Quercetin liposomes attenuated the degeneration of neurons and 
cholinergic neurons in hippocampus. The elevation of SOD, CAT and GPx activities and the reduction 
of MDA in hippocampus were also observed. Therefore, the neuroprotective of quercetin liposomes 
occurred partly via the reduction of oxidative stress. Conclusion: Our studies suggested that nasal 
administration of quercetin liposomes may be the potential novel therapeutic strategy against 
Alzheimer’s disease. However, further researches are still essential.  
 
Key words: Oxidative stress, Alzheimer’s disease, quercetin liposomes, blood brain barrier  
 
INTRODUCTION 
 
  The global prevalence of Alzheimer’s Disease 
(AD) is dramatically increased. It has been estimated 
that approximate 25 million people worldwide were 
attacked by AD (Mayeux and Sano, 1999). Although, 
the etiology of AD is still unclearly known, free 
radicals have been recognized to be one important 
factor (Butterfield, 2004). At present, most of the 
protective and therapeutic strategies against AD are still 
very limited and requires the more effective strategy. 
Thus, the development of novel therapeutic agent from 
substances possessing antioxidant activity has been 
considered. 
  Quercetin, a flavonoid commonly found in 
various vegetables and fruits (Chu, 2000). It was 
reported to protect against oxidative injury and 
cytotoxicity (Ishige et al., 2001). In addition, oral 
administration of quercetin was also able to improve 
learning and memory ability (Wattanathorn et al., 
2007). However, the poor absorption and difficulty to 
pass Blood-Brain-Barrier (BBB) appear to be the big 
burden for its action particularly in the central nervous 
system (Boer et al., 2005; Youdim et al., 2004).  
  Liposomes have long been used as a Drug Delivery 
System (DDS) to the brain, because the particles can 
entrap the compounds and prevent rapid elimination or 
degradation as well as promote penetration through the 
BBB which in turn decrease the effective dose (Sharma 
and Sharma, 1997). In addition, they do not elicit 
negative biological responses that generally occur when 
a foreign material is introduced in the system. These Am. J. Applied Sci., 7 (4): 480-485, 2010 
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lipid vesicles are non-toxic, non-immunogenic, 
noncarcinogenic, non-thrombogenic and biodegradable 
(Sinha et al., 2001). 
  Recently, it had been demonstrated that nasal route, 
a noninvasive delivery system, could produce higher 
bioavailability than oral route due to the decrease 
hepatic metabolism, shorter distance to brain target and 
easy penetration through the brain (Wang et al., 2006; 
Illum, 2004). Based on the beneficial effects of 
quercetin and nasal delivery system, we hypothesized 
that quercetin liposomes could protect against 
neurodegeneration in AD. At present, less scientific 
evidence about this issue is available. Therefore, this 
study was carried out to evaluate the protective effect of 
nasal administration of quercetin liposomes against 
neurodegeneration and its possible mechanism in 
animal model of AD. 
 
MATERIALS AND METHODS 
 
Animals: Adult male Wistar rats (180-200 g, 8 weeks 
old) were obtained from National Animal Center, 
Salaya, Nakorn Pathom and were housed in group of 6 
per cage in standard metal cages at 22±2°C on 12:12 h 
light-dark cycle. All animals were given access to food 
and water ad libitum. The experiments were performed 
after the approval of protocol by the Ethical Committee 
of the Institution and every effort was made to 
minimize animal suffering in accordance with the 
internationally accepted principles for laboratory use 
and care of European Community (EEC directive of 
1986; 86/609/EEC). 
 
Experimental protocol: The animals were divided into 
5 groups of 8 each as following:  
 
•  Liposomes + ACSF: The animals in this group 
were administered free liposomes via nasal route 
then they were administered artificial cerebrospinal 
fluid or ACSF bilaterally via 
intracerebroventricular route. 
•  PEG + ACSF: The rats in this group were 
administered polyethylene glycol or PEG which 
used as vehicle of quercetin liposomes via nasal 
route and subjected to ACSF administration. 
•  Free liposomes + AF64A: All rats were 
administered free liposomes via nasal route then, 
they were administered AF64A bilaterally via 
intracerebroventricular route. 
•  PEG + AF64A: The animals were administered 
PEG via nasal route then they were administered 
AF64A as mentioned in group 3. 
•  QCL + AF64A: The rats in this group were 
administered quercetin liposomes via nasal route, 
then they were administered AF64A. The animals 
were administered the assigned substance at a 
period of 2 weeks before and 1 week after the 
administration of AF64A or ACSF. 
 
Preparation and administration of liposomes: 
Quercetin dehydrate (98%), high-purity Egg L-α-
Phosphatidylcholine, Type XVI-E (EPC) and 
Cholesterol (CHOL) were prepared as quercetin 
encapsulated liposomes. All animals were administered 
quercetin liposomes, containing 0.5 mg of quercetin in 
20 μL (dose = 20 μg), or liposomes without quercetin at 
the same volume via nasal route with a micropipette at 
a period of 2 weeks before and 1 week after AF64A or 
Artificial Cerebrospinal Fluid (ACSF) administration.  
 
AF64A administration: After being anesthetized, the 
animals were bilaterally administered (2 nmol/2 μL) 
AF64A which previously described (Fisher et al., 
1982) or ACSF) via intracerebroventricular route 
according to the following co-ordinates: (from the 
bregma): posterior 0.8 mm, lateral ± 1.5 mm and 
ventral (from dura) 3.6 mm.  
 
Determination of neurons density: After 1 week of 
lesion, they were sacrificed and removed the brains to 
determine the density of neurons and cholinergic 
neurons in hippocampus using histochemical and 
immunohistochemical techniques (Wood and Warnke, 
1981).  
 
Biochemical assays: Hippocampal homogenate was 
prepared in 50 mM phosphate buffer solution (pH 7) 
and determined Superoxide Dismutase (SOD), Catalase 
(CAT) and Glutathione Peroxidase (GPx) activities 
according to the methods of McCord and Fridovich 
(1969); Goldblith and Proctor (1950) and Ellman 
(1959) whereas Malondialdehide (MDA) level were 
determined using Ohkawa et al. (1979). Protein 
concentration was measured by Lowry et al. (1951). 
 
Statistical analysis: Results were expressed as mean ± 
SEM and determined statistical significance using 
ANOVA, followed by Duncan’s test. The significance 
was regarded at p-value<0.05. 
 
RESULTS 
 
  Both liposomes and PEG had been previously 
demonstrated to produce no harmful effect on neuron 
density. The administration of AF64A in either 
liposomes or PEG treated groups significantly 
decreased the neuron density in CA1, CA2, CA3 and 
dentate gyrus (p-value<0.001 all; compared to both 
liposomes + ACSF and PEG + ACSF). Surprisingly, 
quercetin liposomes administration could reverse these 
changes (p-value<0.001 all; compared to liposomes + 
ACSF and PEG + AF64A) as shown in Fig. 1.  Am. J. Applied Sci., 7 (4): 480-485, 2010 
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Table 1: Effect nasal administration of quercetin liposomes on the activities of SOD, CAT, GPx and the levels of lipid peroxidation in animal 
model of AD induced by AF64A  
Experimental conditions  SOD (U mg
−1 protein)  CAT (U mg
−1 protein)  GPx (U mg
−1 protein)  MDA (U mg
−1 protein) 
Liposomes + ACSF  16.80±0.13  18.10±4.55  14.44±0.12  1.45±0.11 
PEG + ACSF  16.41±1.27  18.67±3.84  14.41±0.11  1.48±0.17 
Liposomes+AF64A 11.20±0.17
*# 16.14±1.48
*# 11.20±0.47
*# 2.48±0.27
*# 
PEG + AF64A  12.24±1.90
*# 16.00±1.73
*# 11.87±0.22
*# 2.49±0.26
*# 
QCL + AF64A  22.50±0.12
*#,a,b 19.80±3.43
*#,a,b 18.31±0.33
*#,a,b 1.19±0.13
*#,a,b 
Results are expressed as mean ± SEM; 
*: p-value<0.001 compared with liposomes + ACSF treated group; 
#: p-value<0.001 compared with PEG + 
ACSF treated group; 
a: p-value<0.001 compared with liposomes + AF64A treated group; 
b: p-value<0.001 compared with PEG + AF64A treated 
group 
 
 
 
Fig.  1:  Effect nasal administration of quercetin 
liposomes on the density of neurons in 
hippocampus. (N = 8) Results were expressed as 
mean ± SEM. 
*: p-value<0.001 compared with 
liposomes + ACSF treated group; 
#: p-
value<0.001 compared with PEG + ACSF 
treated group; 
a: p-value<0.001 compared with 
liposomes + AF64A treated group; 
b: p-
value<0.001 compared with PEG + AF64A 
treated group 
 
  We also determined the effect of all interventions 
mentioned earlier on the density of cholinergic 
neurons in hippocampus as shown in Fig. 2. It was 
found that quercetin liposomes also reversed the 
reduction of cholinergic neurons induced by AF64A in 
all subregions of hippocampus mentioned above.  
  In order to determine the possible underlying 
mechanism of quercetin liposomes, we had determined 
the effect of quercetin liposomes on oxidative stress 
indices including the level of Malondialdehide (MDA), 
a product of lipid peroxidation product and the 
activities of scavenger enzymes including SOD, CAT 
and GPx in hippocampus as shown in Table 1. Our 
result showed that both liposomes + AF64A and PEG + 
AF64A groups generated oxidative stress in rat brain, 
by decreasing the activities of SOD, CAT and GPx, 
while increasing the lipid peroxidation. Quercetin 
liposomes were found most effective in restoring 
inherent antioxidant system.  
 
 
Fig.  2:  Effect nasal administration of quercetin 
liposomes on the density of cholinergic neurons 
in hippocampus. Results are expressed as mean 
± SEM. 
*: p-value<0.001 compared with 
liposomes + ACSF treated group; 
#: p-
value<0.001 compared with PEG+ACSF treated 
group; 
a: p-value<0.001 compared with 
liposomes + AF64A treated group; 
b: p-
value<0.001 compared with PEG + AF64A 
treated group 
 
DISCUSSION 
 
  This is the first investigation that extends available 
data on nasal administration of quercetin liposomes 
protective effect against neurodegeneration in animal 
model of AD. Our results showed that quercetin 
liposomes significantly increased the survival neurons 
and cholinergic neurons density in hippocampus and 
reversed the biochemical alterations seen in 
hippocampus induced by AF64A. 
  Various degrees of cognitive impairment were 
reported to be associated with cholinergic neuronal loss 
and dysfunction especially in AD (Bondy, 1995). A 
cholinergic function was previously reported to be 
required for short-term memory process and the 
cholinergic dysfunction also played a crucial role for 
short term memory deficit in AD (Galizia, 1984). 
Recently, a pile of evidence suggested that the prime 
candidate responsible for producing the neuronal 
changes mediating these cognitive deficits appeared to Am. J. Applied Sci., 7 (4): 480-485, 2010 
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be free radicals and oxidative stress generated 
(Mattson, 2004; Antuti-Castelvetri et al., 2000). 
Therefore, many studies focused on the beneficial 
effects of supplement possessing a capability to 
improve cholinergic function and antioxidant activity 
were also considered to be a potential candidate for 
neuroprotective agent against AD.  
  Quercetin, a main flavonoid found in fruits, 
vegetables and beverages, was reported to possess 
antioxidant   and  cognition  (Boots  et  al.,  2008; 
Reiter  et al., 2009). Previous studies confirm that 
quercetin supplementation improve memory deficit 
condition induced by reserpine in mice (Naumenko and 
Kulikov, 2006). However, it was reported that quercetin 
was easily metabolized after absorption (Manach et al., 
2004). Our study found it worthwhile to use the vesicle 
mediated carrier system particularly liposomes to 
encapsulated the quercetin against Alzheimer’s 
condition induced by AF64A as well as oxidative 
stress. 
  Intracerebroventricular injection by AF64A has 
been described as an appropriate the substance to 
destroy the cholinergic system (Hanin, 1996; 
McDonald and Overmier, 1998). In addition, it could 
increase oxidative stress in all area of hippocampus, the 
areas contribution important role on learning leading to 
the neurodegeneration in the mentioned areas resulting 
in learning and memory deficit (Gulyaeva et al., 1996) 
as those observed in AD. 
  In the present study, the results show that in the 
AF64A with nasal administration of free liposomes and 
AF64A with nasal administration of PEG treated 
groups, there were the reduction of survival neurons 
and cholinergic neurons in all areas of hippocampus. 
Moreover, the reduction of scavenging enzymes 
activities including Superoxide Dismutase (SOD), 
Catalase (CAT) and Glutathione Peroxidase (GPx), 
while enhanced the level of Malondialdehyde (MDA), 
which is an indicative of lipid peroxidation were appear 
in these groups. These results are in conformity with 
other workers who have demonstrated cognitive 
impairment after induced by AF64A in rats (Hanin, 
1996; McDonald and Overmier, 1998; Gulyaeva et al., 
1996).  
  No unexpected mortality of any animals occurred 
after nasal administration of quercetin liposomes used 
in the present study. As a result, vesicles were 
considered to be safe at the dosing schedule used. 
Interestingly, in AF64A with nasal administration of 
quercetin liposomes treated group, the rats showed 
significantly improved the density of survival neurons 
and cholinergic neurons in all areas of hippocampus as 
compared to the AF64A + PEG or free liposomes 
treated animals. Moreover, it was notable that the 
density of cholinergic neurons of quercetin liposomes 
plus AF64A treated group were higher than those 
obtained from the liposomes plus ACSF and PEG plus 
ACSF treated group. This suggests that quercetin 
liposomes not only the neuroprotective effect but also 
the neurotrophic effect to stimulate the neurogenesis in 
hippocampus. Previous study demonstrated that the 
neurogenesis could occur throughout adulthood 
especially in hippocampus and subventricular zone of 
lateral ventricle (Hagg, 2005). Numerous factors had 
been reported to be regulators of the adult neurogenesis. 
To clarify this issue, further researches are still 
required. 
  Extensive evidence exists for lipid peroxidation 
being an important mechanism of neurodegeneration in 
the AD (Liu et al., 2003). Prophylactic treatment with 
nasal administration of quercetin liposomes 
significantly reversed the impact of oxidative 
alterations (MDA, SOD, CAT and GPx) seen in 
Alzheimer’s condition induced by AF64A; this shows 
the antioxidant potential of quercetin liposomes via 
nasal administration.  
  The mechanism how quercetin liposomes could 
decrease lipid peroxidation and improve its antioxidant 
systems against Alzheimer’s condition induced by 
AF64A is not known, but it may be presumed that after 
entering the brain, the quercetin or its derivative might 
increase the activities of scavenger enzymes mentioned 
earlier and resulted in the decrease excess free radicals, 
which in turn decreased the lipid peroxidation process 
leading to the reduction of MDA as shown in this study. 
These results are in accordance with the report of 
quercetin liposomes effect to decrease lipid 
peroxidation and increase scavenger enzymes activities 
in rat brain by the induction of cerebral ischemia and 
reperfusion (Sarkar and Das, 2006). However, the 
method to prepare the quercetin liposomes and the 
model to induce the oxidative damage were different. 
  Our results demonstrated that nasal administration 
of quercetin encapsulated liposomes was a potential 
novel strategy to protect against neurodegeneration in 
hippocampus. It could produce beneficial effect with 
very much low dose. Based on the previous findings, 
the decrease effective dose might be associated with 
many factors including the increase opportunity to 
transfer directly from the olfactory mucosa along the 
olfactory  pathway  to  the central nervous system 
(Cho  et al., 2006) via bypassing the Blood-Brain 
Barrier (BBB), which prevented some CNS-active 
drugs from reaching the brain (Behl et al., 1998). In 
addition, it could also decrease the influence of the first 
pass metabolism (Krauze, 2006). However, the main Am. J. Applied Sci., 7 (4): 480-485, 2010 
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proposed pathway of quercetin delivery via nasal 
administration was different. It was likely to permeate 
through the subarachnoid space through the olfactory 
epithelium and found in the CSF later, because the 
liposomes behaved as semilipophilic particles. 
Therefore, quercetin liposomes could rapidly absorb 
into the CSF. Investigation of quercetin absorption and 
distribution after administered via nasal route would be 
of value for future studies.  
 
CONCLUSION 
 
  These results provide experimental evidence for 
the potential beneficial actions of quercetin liposomes 
via nasal administration to protect against AD. Further 
studies are necessary to determine if nasal 
administration of quercetin liposomes could be a 
potential strategy for the clinical management of AD.  
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